Evidence map›Paper›PMID 40386274›Full record

ArticleTranslational cancer research2025

Efficacy of three lung cancer prediction models in diagnosing benign and malignant pulmonary nodules.

Hesen Wu, Xingyi Chen, Xiaoming Feng, Wei He, Duilio Divisi, Jimmy T Efird, José Franco, Xuemin Guo

Abstract read
In one paragraph

Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hesen WuCenter for Clinical Medicine Diagnosis, Meizhou People's Hospital, Meizhou, China.
Xingyi ChenMedical College of Jiaying University, Meizhou, China.
Xiaoming FengMedical College of Jiaying University, Meizhou, China.
Wei HeGuangdong Engineering Technological Research Center of Clinical Molecular Diagnosis and Antibody Drugs, Meizhou, China.
Duilio DivisiDepartment of Life, Health and Environmental Sciences, University of L'Aquila, Thoracic Surgery Unit, "Giuseppe Mazzini" Hospital of Teramo, Teramo, Italy.
Jimmy T EfirdVA Cooperative Studies Program Coordinating Center, Boston, MA, USA.
José FrancoDepartment of Pneumology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Xuemin GuoCenter for Clinical Medicine Diagnosis, Meizhou People's Hospital, Meizhou, China.ORCID https://orcid.org/0000-0003-2929-7461

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The predictive models for malignant lung nodules have been developed, but need further validation and optimization for broader clinical use. This study aimed to compare the diagnostic efficacy of the Mayo model, Peking University People's Hospital (PKUPH) model, and the lung cancer biomarker panel (LCBP) model in distinguishing between benign and malignant pulmonary nodules, providing valuable clinical research data for the early diagnosis of lung cancer. Methods: Clinical and imaging data of patients diagnosed with pulmonary nodules at Meizhou People's Hospital from March 2021 through January 2023 were collected. Data from patients with benign pulmonary nodules during the same period, who served as negative referents, were also gathered. The Mayo model, PKUPH model, and LCBP model were used to clinically validate lung cancer prediction rates. The receiver operating characteristic (ROC) curves and statistical significance comparing the areas under the curve (AUCs) for each model were evaluated. Results: A total of 428 patients were included: 160 females and 268 males. The noncancer group included 218 cases (50.93%), and the cancer group included 210 cases (49.07%). The AUC values of the three models were as follows: Mayo model, 0.783; PKUPH model, 0.726; and LCBP model, 0.759. (I) For the Mayo model, at the maximum Youden index, the concordance rate was 74.3%, the sensitivity 85.71%, the specificity 63.30%, the positive predictive value 69.23%, the negative predictive value 82.14%, the positive likelihood ratio 2.335, and the negative likelihood ratio 0.226. (II) For the PKUPH model, at the maximum Youden index, the concordance rate was 70.3%, the sensitivity 84.29%, the specificity 56.88%, the positive predictive value 65.31%, the negative predictive value 78.98%, the positive likelihood ratio 1.955, and the negative likelihood ratio 0.276. (III) For the LCBP model, at the maximum Youden index, the concordance rate was 75.0%, the sensitivity 72.38%, the specificity 77.52%, the positive predictive value 75.62%, the negative predictive value 74.45%, the positive likelihood ratio 3.220, and the negative likelihood ratio 0.356. Conclusions: All three predictive models exhibit clinical applicability, with minimal differences in diagnostic efficacy. The LCBP model outperformed both the Mayo and PKUPH models in diagnostic performance, showing greater diagnostic value for the Chinese population. However, there is still room for optimization in each model.

Indexed as

diagnostic efficacylung cancerlung cancer prediction modelPulmonary nodules

Identifiers

PMID40386274
PMCPMC12079300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.